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1047-180 Low High-Density Lipoprotein Cholesterol, 
Hypertension, Diabetes, but Not High Low-Density 
Lipoprotein Cholesterol as Predictors of Acute 
Coronary Syndrome in Northern Area of Japan: A Case-
Control Study
Ichiro Sakuma, Noriaki Kishimoto, Naotsugu Oyama, Yasuaki Saijo, Satoshi Nawate, 
Takamitsu Souma, Kazuhiko Nagai, Kazushi Urasawa, Reiko Kishi, Akira Kitabatake, 
Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background: Recent rapid change in life style has resulted in a gradual increase in cor-
onary heart disease (CHD) in Japan, although its incidence is still one fourth of that of
US. Mean total cholesterol (TC) level in Japan, for example, was far less than that in US
20 years ago, but now mean TC of Japanese females surpasses that of American
females. However, since the chronological accumulation of such a risk factor (RF) in
Japan is still lighter than that in US and Europe, RFs for CHD in Japan may differ.
Method: We conducted a retrospective case-control study enrolling 722 Japanese
patients who suffered their first acute coronary syndrome (ACS) and were transferred to
24 hospitals in the northern island of Japan. As controls, 1748 age-, sex- and residence-
matched subjects were randomly picked up from a data base of one regional health
check-up organization. We assessed associations between premorbid variable and the
RFs of ACS by conditional logistic regression analysis. Result: The most important pre-
dictor of ACS in men was low HDL-cholesterol (C) (odds ratio, OR: 6.159, p<0.001). His-
tory of hypertension (HT) and that of diabetes (DM) were also independent RFs (OR:
2.727, p<0.001 and OR: 1.815, p<0.001, respectively). On the other hands, in women,
HT was the most important RF (OR: 5.767, p<0.001). Low HDL-C, hypertriglyceridemia
and DM were also independent RFs (OR: 3.427, p<0.01, OR: 2.298, p<0.05 and OR:
2.42, p<0.05, respectively). However, OR of high TC was significantly less than 1.0 and,
that of high LDL-C was not different from unity in both sexes. The reason why TC and
LDL-C did not become the predictors of ACS in the present subjects was because there
were many ACS patients whose TC and LDL-C were normal ; however, of note, their
HDL-C was low. Thus, in Japanese northern area, low HDL-C, HT, DM and hypertriglyc-
eridemia, representing metabolic syndrome, were significant predictors of ACS. Conclu-
sion: The present results indicate the importance of metabolic syndrome as the cause of
CHD in the population whose LDL-C has not been high, and would further imply the
future tendency of CHD risks in US and Europe where recent nutritional education pro-
grams for general population to lower LDL-C have been effective.
1047-181 High-Density Lipoprotein-Mediated Cholesterol Efflux 
From Cells Is a Strong Independent Predictor of 
Cardiovascular Risk
Julio A. Chirinos, Juan Pablo Zambrano, Simon C. Chakko, Alan Schob, Guido O. Perez, 
Armando J. Mendez, Miami VA Medical Center, Miami, FL, Diabetes Research Institute, 
Miami, FL
Background
Low levels of high density lipoproteins (HDL) are recognized as a risk factor for coronary
artery disease (CAD), presumably related to the ability of HDL to mediate reverse choles-
terol transport from cells. We aimed to determine whether this function of HDL was
related to the presence of CAD or predicts a primary combined endpoint ([CE], death,
myocardial infarction, unstable angina, revascularization or stroke) or all-cause mortality
(ACM).
Methods
129 men (mean age 62.6 years)undergoing coronary angiography at the Miami VA Medi-
cal Center (10/98 - 05/99) were prospectively followed for 3 years. Blood samples were
analyzed for lipid, lipoproteins and CRP levels. ATP binding cassette transporter 1
(ABCA-1) dependent cholesterol efflux was defined as the ability of serum to decrease
the pool of cholesterol available for esterification by the acylCoA:cholesterol acyltrans-
ferase reaction after incubating cultured fibroblasts with medium containing 2% patient
serum for 6 hours
Results
69% of patients had CAD and about 1/3 smoked or had diabetes. Efflux did not correlate
with HDL levels or the presence of CAD. The mean follow up time was 1047 ± 42 days.
41% of patients reached the CE and 19% died. Patients in the highest efflux tertile had
significantly higher risk of reaching the CE (p=0.007; HR = 1.57; 95%CI 1.12-2.22). Efflux
was also predictive of ACM (p=0.009; HR 2.27; 95%CI 1.21-4.23). After correction for
age, body mass index, blood pressure, ejection fraction, smoking, diabetes, family history
of CAD, triglyceride, HDL, LDL, CRP, apoA-I, apoA-II, apoB, and statin use, efflux
remained predictive of the CE (p<0.0001; HR 3.19 95%CI 1.91-5.34) and ACM (p=0.006;
HR=2.60; 95%CI 1.12-1.06). Stepwise Cox Regression Analysis selected the efflux ter-
tile (p<0.0001; HR 2.63 95%CI 1.69-4.08), CRP (p=0.0001; HR=1.61 95%CI 1.26-2.06)
and LDL cholesterol (p=0.14) as independent predictors of the CE.
Conclusions
Cholesterol efflux, an in vitro measure of HDL function, was a strong, independent
adverse predictor of cardiovascular events and ACM. This predictive value is indepen-
dent of classical risk factors, HDL lipid or apoprotein levels.
1047-182 The Role of Triglycerides, Very Low Density 
Lipoproteins, and Triglyceride Rich Atherogenic 
Lipoprotein in Predicting Premature Heart Disease
Kwame Osei Akosah, Ana Mari Schaper, Vicki Lynn McHugh, Sharon Ione Barnhart, 
Patricia A. Perlock, Troy Anthony Haider, Michelle Ann Mathiason, Gundersen Lutheran 
Health System, La Crosse, WI
Background: Meta-analysis of prospective studies indicates that triglycerides are inde-
pendently predictive of coronary artery disease (CAD). The role of triglycerides may be
more important in this era of increasing rates of obesity. We previously reported that cur-
rent guidelines based on LDL cholesterol under-estimate disease risk in young adults.
Our population was characterized by high rates of obesity and the role of triglyceride rich
atherogenic lipoproteins was not examined.
Objective: To determine the role of triglyceride rich atherogenic lipoproteins in young
adults evaluated for primary prevention.
Method: Young adults without any history of CAD or statin therapy undergoing elective
coronary angiography were prospectively studied. Fasting blood samples were sent for
lipid and advanced lipoprotein testing (LipoScience, Inc.). Framingham risk scores were
calculated for each subject. CAD was defined as stenosis > 50%.
Results: 254 young men and women, mean age 53 ± 8 were enrolled. Group 1 had CAD
(n=73). Group 2 had no CAD (n=181). Mean total (202 versus 193 mg/dL), LDL (128 ver-
sus 120 mg/dL), and HDL cholesterol (49 versus 53 mg/dL) were similar in group 1 and
group 2. In contrast, triglyceride (170 versus 138 mg/dL, p =0.002), VLDL (133 versus
102 mg/dL, p=0.003), large VLDL (68 versus 46 mg/dL, p=0.01), and VLDL particle con-
centration (79 versus 69 mg/dL, p=0.01) were significantly higher in group 1 versus group
2.The odds ratios (OR) and confidence intervals (CI) for subjects in the highest as com-
pared with the lowest quartile were as follows: triglyceride-2.5 (CI: 1.2-5.4, p=0.02),
VLDL-2.5 (CI: 1.2-5.4, p=0.02), VLDL particle concentration- 2.3 (CI: 1.1-4.9, p=0.04),
and large VLDL- 2.4 (CI: 1.1-5.0, p=0.02). Large VLDL (OR: 2.9, CI: 1.6-5.4) was the
only independent predictor of CAD in the multivariate model.
Conclusion: In the evaluation of young adults in a population with high obesity rates,
triglycerides and triglyceride rich atherogenic lipoprotein may be valuable in risk assess-
ment.
1047-183 Impaired Reverse Cholesterol Transport in Asian Indian 
Males Compared With Females Assessed by Nuclear 
Magnetic Resonance Spectroscopy
Narendra C. Bhalodkar, Enas A. Enas, Steve Blum, Bronx Lebanon Hospital Center, 
Bronx, NY
Background: Asian Indian (AI) males have higher incidence of CAD compared to
females. Large size HDL (LHDL) offers CAD protection and reflects reverse cholesterol
transport. Heterogeneity with respect to size, density & composition of HDL may explain
higher incidence of CAD in males. Methods: Cohort: 407 relatively healthy AIs. Nuclear
Magnetic Resonance Spectroscopy (NMRS) was used to determine the concentrations
of 5HDL subclasses of different particle sizes. HDL was subdivided in two categories,
LHDL & Small HDL. Subjects (n=77) on anti-lipid, thyroid or hormone replacement ther-
apy were excluded. Results: Among remaining 330 subjects, 119 (mean age 48±11)
were females and 211(mean age 50±11) were males. CAD was twice as common in
males, 8% compared to 3.8%. Risk factors for CAD were similar in both genders: Age,
DM, HTN, h/o high cholesterol, & smoking. Total cholesterol (205 ± 39 vs. 209 ± 40,
p=0.38) & LDL cholesterol (135 ± 31 vs. 137 ±33, p=0.58) were nearly identical. HDL by
NMRS are tabulated. Conclusions: Despite twofold higher CAD among AI males, both
genders AIs have similar risk factors for CAD, total cholesterol & LDL levels. However
males exhibit significantly impaired reverse cholesterol transport as reflected by signifi-
cantly lower HDL concentrations, smaller HDL particle sizes, reduced levels of LHDL &
higher levels of Small HDL, which may partly explain higher rates of CAD among males.
Further studies are warranted to determine that these differences can be extended to
other race, sex groups.
1047-184 Long-Term Effectiveness of the Management of 
Dyslipidemia With a Planned Strategy of Management
Asanga Samarakoon, Jo Griffiths, Karen MacDonald, Rachel Leung, Mano Senaratne, 
Grey Nuns Hospital-University of Alberta, Edmonton, AB, Canada
Background: Despite unequivocal reduction in mortality/morbidity with lipid lowering ther-
apy (LLT) in patients with coronary artery disease (CAD), a substantial proportion remain
un/under-treated. A previous study demonstrated the short-term effectiveness of a
planned strategy of management using a cardiac rehabilitation nurse (CRN) as an inte-
gral mediator in achieving the recommended goals in dyslipidemia.
Methods: Pts with CAD enrolled in the cardiac rehabilitation program (CRP) had their
lipid profiles arranged and followed by the CRN with up-titration of drugs to achieve an
LDL less than 2.6mmol/l. Pts received a booklet tabulating their lipid values with the
goals (for LDL, HDL etc) identified, as well as instructions to follow these up with their
family physicians. Pts were contacted 12-18 months later. All data were collected pro-
spectively.
Results: Of the 1100 consecutive pts (M=864; F=236; Age- Mean 60.0±0.1 SEM yrs; H/O
AMI=24.5%: DM=20.4%: HT=44.0%: F/H of CAD=38.3%), 1040 pts (94.5%)were con-
tacted 15.5±0.4 months after completion of the CRP. 60 pts (5.5%) could not be con-
tacted despite numerous attempts. 867 pts (83.4%), 793pts(78.7%), 580pts(57.7%), 936
pts (92.8%) and 159pts(15.8%) were on LLT, beta-blockers, ACE-inhibitors, ASA and cal-
cium antagonists respectively.
Conclusions: A planned strategy of management using a CRN is effective in achieving
lipid targets and the appropriate use of medications on a long-term basis. However
attempts at weight reduction appear sub-optimal
HDL lipoproteins by NMRS
HDL by NMRS Males (N = 211) Females (N =119) P Value
HDL Levels (mg/dl) 40.7 ± 9.7 52.5 ± 12.1 <0.0001
HDL Size (nm) 8.5 ± 0.31 8.9 ± 0.35 <0.0000001
LHDL Levels (mg/dl) (H3+H4+H5) 21.4 ± 13.9 38.3 ± 15.0 <0.0000001
Small HDL Levels (mg/dl) (H1+H2) 19.7 ± 6.5 14.8 ± 6.7 <0.0000001
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1047-185 Postprandial Lipoproteinemia Exhibits a Bimodal 
Response in Metabolic Syndrome Patients
Robert S. Rosenson, Anna Huskin, Northwestern University, Chicago, IL
Background: Metabolic syndrome is defined by abnormal fasting lipids; however post-
prandial lipemia may provide important insights regarding cardiovascular risk in these
subjects. This study evaluated postprandial lipoprotein responses in metabolic syndrome
subjects.
Methods: 43 subjects (31 M, 12 F) with fasting triglycerides > 150 mg/dL and > 2 other
NCEP criteria for the metabolic syndrome received a NCEP Step 2 diet for 6 months. A
standardized oral fat load (50 g/m2) was given. Plasma samples were collected at base-
line, 3 hours, and 8 hours after the last meal. NMR lipoprofiles were analyzed from refrig-
erated plasma. Data are reported as medians.
Results: 28 subjects had an early TG peak and 16 subjects had a late peak. The lipopro-
tein concentrations are described in the table. Late peakers were significantly older (56.9
± 7.6 vs 50.2 ± 10.3, p = 0.03), had higher fasting glucose levels (88.4 ± 12.5 vs 78.1 ±
16.5, p = 0.04), and tended to have more metabolic syndrome risk factors (p = 0.18).
Clearance of chylomicrons and large VLDL were delayed in late vs early peakers (p <
0.01 for each variable) (Table). Small LDL levels fell less rapidly in late peakers than early
peakers (p = 0.02).
Conclusion: Hypertriglyceridemic subjects with the metabolic syndrome exhibit variable
postprandial lipoprotein responses. Delayed lipoprotein clearance is associated with
older age, higher fasting glucose levels, and more metabolic syndrome risk factors. 
1047-186 Raloxifene Improves Lipoprotein, Apolipoprotein and 
Fibrinogen in Postmenopausal Osteoporotic Women 
With or Without Hypertriglyceridemia
Thomas Dayspring, Yongming Qu, Cheryl A. Keech, North Jersey Institute of 
Menopausal Lipidology, Wayne, NJ, Lilly Research Laboratories, Indianapolis, IN
Background: Raloxifene (RLX) is used for prevention and treatment of postmenopausal
osteoporosis and has positive effects on markers of cardiovascular disease, including
lipid lowering. Women with high triglycerides (hTG) are at increased risk of cardiovascu-
lar events.
Methods: We determined the effect of 3 yrs of RLX (60 or 120 mg/d) vs. placebo (PLC)
on lipoproteins, apolipoproteins and fibrinogen in women who were classified as having
hTG (>150 mg/dL) vs. normal TG (nTG, <150mg/dL) at baseline in the Multiple Out-
comes of Raloxifene Evaluation trial. A mixed model repeated measure analysis was
used.
Results: Effect of RLX compared to PLC did not depend on baseline TG status (interac-
tion P>0.1). At baseline, TG levels in hTG (n=446) vs. nTG (n=2213) groups were 204 vs.
91 mg/dL, respectively; hTG women had elevated LDL-C, non-HDL-C, total cholesterol
and low HDL-C (P<.005 vs. nTG). At 3 yrs, RLX improved LDL-C, Apo B, non-HDL-C,
Apo A1, total choelsterol and fibrinogen compared to PLC (both TG groups). RLX was
neutral on HDL-C, but increased Apo A1 compared to PLC in both TG groups. Lipopro-
tein changes occurred at the earliest time point measured (6 mo).
Conclusion: RLX was equally efficacious for nTG and hTG women in improving lipopro-
teins, apolipoproteins and fibrinogen levels.
Table 1. Mean Values (% From Baseline) for Lipoproteins and Fibrinogen at 3 Years 
*P<.01 vs. baseline, for all groups indicated
†RLX vs. PLC within TG group, P<.03
All levels expressed as mg/dL except for fibrinogen (g/L)
1047-187 Cholesterol Goal Attainment Is Associated With Lower 
Incidence of Cardiovascular Events and Cost of Care
Linus Jönsson, Fredrik Borgström, Jan Stålhammar, Evo Alemao, Donald Dongping Yin, 
Karolinska Institutet, Stockholm, Sweden
Introduction: Lowering elevated cholesterol decreases cardiovascular (CV) morbidity
and mortality. However, a majority of treated patients do not reach recommended thera-
peutic goal (LDL < 3 mmol/l and total cholesterol < 5 mmol/l according to European
guidelines). This study describes patterns of lipid-lowering therapy in Swedish primary
care and estimates rate and determinants of goal attainment and its effect on CV events
and costs of care.
Materials and Methods: Total of 9789 patients receiving lipid-lowering treatment
between 1993 and 2003 were included from 29 primary care centers in a defined geo-
graphic area. Data were gathered on health care visits, hospitalizations, lab tests, phar-
maceuticals, co-morbidity and risk factors though retrospective review of computerized
medical records and inpatient and mortality registers. Regression methods were used to
control for baseline differences and estimate event incidences and costs of care.
Results: Within first year of treatment, 4.9% patients were titrated to a higher dose, 2.9%
received an add-on drug, 0.9% had a decrease in dosage and 15.3% discontinued treat-
ment. Average reduction in LDL was 31.1% for patients treated with statin. Overall 28.5%
evaluable patients attained the lipid goals within 3 months, 29.7% within one year. Goal
attainment was significantly higher in patients with low baseline cholesterol level (OR =
0.53), older age (OR = 1.01), prior CV events (OR = 1.53), and who received dose titra-
tion or add-on treatment (OR = 2.27). Incidence of MI, stroke and revascularization pro-
cedures was 16.8, 13.4 and 8.9 per 1000 patients per year. Total annual incidence of CV
events was 155.0 and 18.2 per 1000 patients with and without prior CV events, respec-
tively. Patients who attained lipid goals had 31.4% lower incidence of subsequent events
and lower total discounted costs compared to those not attaining lipid goals (p<0.05) dur-
ing period of observation, controlling for age, gender, previous CHD and diabetes.
Conclusions: A majority (70%) of patients on current lipid management strategy do not
attain lipid goals. However, goal attainment is associated with superior outcome in terms
of reducing CV event rates and health care costs.
1047-188 The Ratio of Oxidized Low-Density to High-Density 
Lipoproteins Is an Independent Predictor of Acute 
Myocardial Infarction in Unstable Coronary Artery 
Disease
Nina Johnston, Tomas Jernberg, Bo Lagerqvist, Agneta Siegbahn, Lars Wallentin, 
University Hospital, Uppsala, Sweden
Background: Early risk stratification is essential in patients with unstable coronary artery
disease (UCAD), i.e. unstable angina or non ST-elevation myocardial infarction (MI). Oxi-
dized low-density lipoprotein (OxLDL) is involved in numerous pathophysiological mecha-
nisms in the development of the disease .The aim of this study was to examine the
prognostic value of OxLDL in this population.
Methods: OxLDL was analyzed in 432 patients with unstable angina or non ST-elevation
MI included in the FRISC II trial. End points were death and myocardial infarction after 2
years.
Results: The median level of OxLDL was 76 (25:th-75:th percentile: 63-88 U/l). The rate
of death and myocardial infarction in relation to OxLDL and the ratio of OxLDL to high-
density lipoprotein (HDL) is shown in the table below . When adjusted for known predic-
tors of adverse outcome, including age, gender, diabetes, prior myocardial infarction, ST-
segment depression, troponin T and treatment strategy (non-invasive/ invasive), the ratio
of OxLDL to HDL was independently associated to the risk of future MI, odds-ratio
(95%CI): 2.23 (1.20-4.15).
CHOL
(mmol/L)
LDL
(mmol/L)
HDL
(mmol/L)
TG
(mmol/L)
Smoking
(%)
Weight
(kg)
Baseline 5.46 3.41 1.08 2.18 34.5 83.1
End of CREP 4.16 2.30 1.12 1.64 10.6 82.0
Follow-up 4.40 2.50 1.14 1.69 12.7 83.3
Variable Early 
Peakers (3 
hours)
Late 
Peakers (8 
hours)
% 
Change
0 to 3 
hours
% 
Change
0 to 8 
hours
% 
Chan
ge
3 to 8 
hours
% 
Chan
ge
0 to 3 
hours
% Change
0 to 8 hours
% 
Chan
ge
3 to 8 
hours
p-value for 
% change
0 to 3 
hours
p-value for 
% change
0 to 8 
hours
p-value for 
% change
3 to 8 
hours
TG 55.1 11.9 -28.8 42.0 52.9 6.7 0.04 <0.01 <0.01
LDL-C 7.0 5.1 -0.6 5.5 9.1 -0.4 0.75 0.85 0.48
HDL-C -8.9 3.9 14.2 -3.1 2.1 1.6 0.10 0.49 0.05
Chylomi
crons
1342.1 151.1 -83.8 609.5 590.9 -8.8 0.27 0.04 <0.01
Large 
VLDL
128.8 42.8 -33.1 56.7 131.1 36.9 0.05 0.04 <0.01
Large 
HDL
-6.0 -6.4 3.8 -9.0 -22.2 -17.5 0.99 0.26 0.03
Small 
LDL
-9.2 -54.6 -48.2 -6.7 -9.5 -6.1 0.94 0.17 0.02
High Triglyceride Normal Triglyceride
Placebo Raloxifene (pooled) Placebo Raloxifene (pooled)
LDL-C* 158
(-2.3)
136†
(-16.5)
151
(-0.6)
135†
(-12.7)
APO B* 158
(-7.5)
145†
(-15.8)
138
(-2.9)
128†
(-11.3)
Non-HDL-C* 195
(-3.9)
173†
(-14.7)
169
(-0.6)
154†
(-10.5)
HDL-C* 49
(5.0)
51
(8.1)
65
(6.3)
65
(6.0)
APO A1 144
(1.9)
151*†
(4.3)
155
(0.2)
159†
(2.2)
Total-C 244*
(-2.5)
225*†
(-10.3)
234
(0.9)
219*†
(-6.4)
Fibrinogen 3.4
(2.9)
2.9*†
(-12.1)
3.3
(6.7)
2.9*†
(-8.9)
